HC Wainwright set a $33.00 target price on Audentes Therapeutics (NASDAQ:BOLD) in a research report released on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.
“Our Buy rating and $33 price target on shares of Audentes are based on sum-of-the-parts analysis of the company’s pipeline. We value the XLMTM commercial opportunity at $17/share, and CN at $16/share, each of which are based on a 5x P/ S multiple on peak sales of roughly $579M (XLMTM peak sales of about $300M and CN peak sales of approximately $279M in FY2025), discounted at 10% over a 7-year period. Our 5x P/S multiple is below the lower end of historic M&A within the sector (typically in the range of 7-9x).”,” HC Wainwright’s analyst wrote.
Several other research analysts also recently commented on the company. ValuEngine downgraded Audentes Therapeutics from a buy rating to a hold rating in a report on Friday, October 12th. Wedbush decreased their price objective on Audentes Therapeutics from $52.00 to $49.00 and set an outperform rating on the stock in a report on Monday, October 8th. BidaskClub downgraded Audentes Therapeutics from a hold rating to a sell rating in a report on Wednesday, August 1st. Guggenheim initiated coverage on Audentes Therapeutics in a report on Tuesday, October 9th. They issued a neutral rating on the stock. Finally, Cowen initiated coverage on Audentes Therapeutics in a report on Friday, September 7th. They issued a sell rating and a $20.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $36.00.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.97) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.09). During the same period in the previous year, the firm posted ($0.88) earnings per share. Analysts expect that Audentes Therapeutics will post -3.39 earnings per share for the current year.
In related news, Director Louis G. Lange sold 33,000 shares of the firm’s stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $37.38, for a total value of $1,233,540.00. Following the sale, the director now directly owns 365,999 shares of the company’s stock, valued at $13,681,042.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew R. Patterson sold 21,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $38.16, for a total value of $801,360.00. Following the completion of the sale, the chief executive officer now directly owns 17,144 shares in the company, valued at $654,215.04. The disclosure for this sale can be found here. Insiders sold 77,039 shares of company stock worth $2,925,260 over the last three months. 6.60% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Partner Investment Management L.P. bought a new stake in shares of Audentes Therapeutics in the second quarter worth about $162,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Audentes Therapeutics in the second quarter worth about $226,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Audentes Therapeutics in the second quarter worth about $231,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Audentes Therapeutics in the second quarter worth about $232,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Audentes Therapeutics in the first quarter worth about $204,000. 96.75% of the stock is currently owned by institutional investors.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Further Reading: Initial Public Offering (IPO)
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.